Market Closed - Nyse 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
3.44 USD -2.82% Intraday chart for Myomo, Inc. +26.47% -31.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Myomo, Inc. Appoints Heather Getz as Class II Director and Chair of Audit Committee CI
Transcript : Myomo, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Earnings Flash (MYO) MYOMO Reports Q4 Revenue $4.8M, vs. Street Est of $4.8M MT
Myomo, Inc. Provides Earnings Guidance for the First Quarter of 2024 CI
Myomo, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Myomo, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Myomo Completes $6 Million Share Offering MT
Myomo to Sell $6 Million of Common Shares in Registered Direct Offering MT
Myomo, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023 CI
Certain Warrants of Myomo, Inc. are subject to a Lock-Up Agreement Ending on 29-NOV-2023. CI
Myomo, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (MYO) MYOMO Posts Q3 Revenue $5.1M, vs. Street Est of $4.2M MT
Transcript : Myomo, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Myomo, Inc. Provides Revenue Guidance for the Full Year of 2023 CI
Myomo, Inc. Announces CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro for Review at the Upcoming HCPCS Public Meeting CI
Myomo Closes Offering of 7.33 Million Shares MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday MT
Myomo Plans Public Offering of Common Shares MT
Transcript : Myomo, Inc., Q2 2023 Earnings Call, Aug 09, 2023
Earnings Flash (MYO) MYOMO Posts Q2 Revenue $6M, vs. Street Est of $5.6M MT
Myomo, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Centers for Medicare and Medicaid Services Accepts Myomo, Inc.'s Application to Classify the MyoPro as A Brace CI
Maxim Initiates Myomo at Buy With $2 Price Target MT
Transcript : Myomo, Inc., Q1 2023 Earnings Call, May 10, 2023
Earnings Flash (MYO) MYOMO Posts Q1 Revenue $3.45M, vs. Street Est of $3.34M MT
Chart Myomo, Inc.
More charts
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. It develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm, and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. It provides devices directly to patients and bill their insurance companies directly. It also sells its products through various other sales channels, including through orthotics and prosthetics providers, the veteran’s administration, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.44 USD
Average target price
6.312 USD
Spread / Average Target
+83.50%
Consensus
  1. Stock Market
  2. Equities
  3. MYO Stock
  4. News Myomo, Inc.
  5. Sector Update: Health Care Stocks Resisting Broader Markets' Slide